Quarterly report pursuant to Section 13 or 15(d)

DEVELOPMENT AWARDS (Details Narrative)

v3.22.2.2
DEVELOPMENT AWARDS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 31, 2020
Jan. 26, 2018
May 31, 2019
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Entity Listings [Line Items]                      
Revenue       $ 0 $ 97,323 $ 0 $ 881,705        
CFF Warrant [Member]                      
Entity Listings [Line Items]                      
Warrant exercisable price per share       $ 13.20   $ 13.20          
Collaboration Agreement [Member] | Cystic Fibrosis Foundation [Member]                      
Entity Listings [Line Items]                      
Royalty payment percentage   10.00%                  
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2b Clinical Trial [Member]                      
Entity Listings [Line Items]                      
Accrued Royalties, Current     $ 2,700,000                
Payments for Royalties     $ 27,000,000                
Proceeds from investments on achieving milestones           $ 25,000,000          
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]                      
Entity Listings [Line Items]                      
Gain Contingency, Unrecorded Amount   $ 25,000,000                  
Investment Agreement [Member] | CFF Warrant [Member]                      
Entity Listings [Line Items]                      
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right       1,000,000   1,000,000          
Warrants and Rights Outstanding, Maturity Date       Jan. 26, 2025   Jan. 26, 2025          
Investment Agreements [Member]                      
Entity Listings [Line Items]                      
Payment term under agreement           Pursuant to the terms of the Investment Agreement and an amendment entered into on June 20, 2022 (the "Investment Agreements"), in the event Corbus licenses the right to develop and commercialize lenabasum to a third party the Company is obligated to pay the CFF 10% of the first $2 million received, 15% of amounts exceeding $2 million up to $5 million and 23% of amounts exceeding $5 million.          
Revenue $ 25,000,000     $ 0 $ 97,323 $ 0 $ 881,705 $ 2,500,000 $ 5,000,000 $ 5,000,000 $ 12,500,000
Investment Agreements [Member] | Cystic Fibrosis Foundation Warrants [Member]                      
Entity Listings [Line Items]                      
Revenue           25,000,000          
Adjustments to Additional Paid in Capital, Warrant Issued           6,215,225          
Revenue to be recognized       $ 18,784,775   $ 18,784,775